Prongay & Murray LLP (“GPM”) continues its investigation on
behalf of GenMark Diagnostics, Inc. (“GenMark” or the “Company”)
investors concerning the Company and its officers’ possible violations
of federal securities laws. To obtain information or aid in the
investigation, please visit the GenMark investigation page on our
On November 2, 2017, GenMark disclosed that the administrative approval
process for ePlex in Europe was taking significantly longer than
expected—in some cases in excess of 180 days—which was affecting revenue
On this news, GenMark’s share price fell $3.00 or approximately 41%, to
close at $4.26 per share on November 3, 2017, thereby injuring investors.
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased GenMark securities, have information or would like to
learn more about these claims, or have any questions concerning this
announcement or your rights or interests with respect to these matters,
please contact Lesley
Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los
Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by
email to [email protected],
or visit our website at www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171110005157/en/